J Psychopharmacol. 2021 Dec;35(12):1441-1448. doi: 10.1177/02698811211034810. Epub 2021 Jul 28.
β-adrenoceptor antagonists and nightmares: A pharmacoepidemiological-pharmacodynamic study.
Journal of psychopharmacology (Oxford, England)
Philippe Garcia, Jean-Louis Montastruc, Vanessa Rousseau, Jacques Hamard, Agnès Sommet, François Montastruc
Affiliations
Affiliations
- Department of Medical and Clinical Pharmacology, Centre of Pharmacovigilance and Pharmacoepidemiology, Faculty of Medicine, Toulouse University Hospital, Toulouse, France.
- CIC 1436, Team PEPSS-Pharmacologie En Population cohorteS et biobanqueS, Toulouse University Hospital, Toulouse, France.
PMID: 34318729
DOI: 10.1177/02698811211034810
Abstract
AIM: To compare different β-adrenoceptor antagonists for the risk of reporting nightmare.
METHODS: The study involved two approaches: first, we investigated in VigiBase
RESULTS: Of the 126,964 reports recorded with β-adrenoceptor antagonists, 1138 (0.9%) were nightmares. The highest risk of reporting a nightmare was found with exposure of pindolol (adjusted ROR 2.82, 95%CI, 2.19-3.61), metoprolol (1.89, 1.66-2.16), and alprenolol (1.77, 1.06-2.97). Compared to use of low lipid solubility β-adrenoceptor antagonists, use of moderate or high lipid solubility β-adrenoceptor antagonists were significantly more associated with nightmare reports (aROR moderate vs. low 1.72, 95%CI 1.47-2.00 and aROR high vs. low 1.84, 95%CI 1.53-2.22). Use of moderate or high 5-HT
CONCLUSION: In our large pharmacovigilance study, nightmares are more frequently reported for pindolol and metoprolol, and among β-adrenoceptor antagonists with high lipid solubility and high 5-HT
Keywords: Beta adrenergic antagonists; VigiBase; adverse drug reactions; nightmare; pharmacoepidemiology; pharmacovigilance
Publication Types
